Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial

Kei Nakashima, Masahiro Aoshima, Satoko Ohfuji, Satoshi Yamawaki, Masahiro Nemoto, Shinya Hasegawa, Satoshi Noma, Masafumi Misawa, Naoto Hosokawa, Makito Yaegashi, Yoshihito Otsuka, Kei Nakashima, Masahiro Aoshima, Satoko Ohfuji, Satoshi Yamawaki, Masahiro Nemoto, Shinya Hasegawa, Satoshi Noma, Masafumi Misawa, Naoto Hosokawa, Makito Yaegashi, Yoshihito Otsuka

Abstract

It is unclear whether simultaneous administration of a 23-valent pneumococcal polysaccharide vaccine (PPSV23) and a quadrivalent influenza vaccine (QIV) produces immunogenicity in older individuals. This study tested the hypothesis that the pneumococcal antibody response elicited by simultaneous administration of PPSV23 and QIV in older individuals is not inferior to that elicited by sequential administration of PPSV23 and QIV. We performed a single-center, randomized, open-label, non-inferiority trial comprising 162 adults aged ≥65 years randomly assigned to either the simultaneous (simultaneous injections of PPSV23 and QIV) or sequential (control; PPSV23 injected 2 weeks after QIV vaccination) groups. Pneumococcal immunoglobulin G (IgG) titers of serotypes 23F, 3, 4, 6B, 14, and 19A were assessed. The primary endpoint was the serotype 23F response rate (a ≥2-fold increase in IgG concentrations 4-6 weeks after PPSV23 vaccination). With the non-inferiority margin set at 20% fewer patients, the response rate of serotype 23F in the simultaneous group (77.8%) was not inferior to that of the sequential group (77.6%; difference, 0.1%; 90% confidence interval, -10.8% to 11.1%). None of the pneumococcal IgG serotype titers were significantly different between the groups 4-6 weeks after vaccination. Simultaneous administration did not show a significant decrease in seroprotection odds ratios for H1N1, H3N2, or B/Phuket influenza strains other than B/Texas. Additionally, simultaneous administration did not increase adverse reactions. Hence, simultaneous administration of PPSV23 and QIV shows an acceptable immunogenicity that is comparable to sequential administration without an increase in adverse reactions. (This study was registered with ClinicalTrials.gov [NCT02592486]).

Keywords: 23-valent pneumococcal polysaccharide vaccine; Elderly population; Immunogenicity; Quadrivalent influenza vaccine; Simultaneous administration.

Figures

Figure 1.
Figure 1.
CONSORT flowchart
Figure 2.
Figure 2.
Differences in the response rates of 23F between the 2 groups (the rate in the simultaneous group minus that in the sequential group)

References

    1. Blasi F, Mantero M, Santus P, Tarsia P. Understanding the burden of pneumococcal disease in adults. Clin Microbiol Infect. 2012;18(Suppl 5):7–14. doi:10.1111/j.1469-0691.2012.03937.x.
    1. Centers for Disease Control and Prevention Estimates of deaths associated with seasonal influenza — United States, 1976–2007. MMWR Morb Mortal Wkly Rep. 2010;59:1057–62. PMID:20798667.
    1. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013:CD000422.
    1. Kohlhammer Y, Schnoor M, Schwartz M, Raspe H, Schafer T. Determinants of influenza and pneumococcal vaccination in elderly people: a systematic review. Public Health. 2007;121:742–51. doi:10.1016/j.puhe.2007.02.011. PMID:17572457
    1. Public Health England Pneumococcal Polysaccharide Vaccine (PPV) coverage report, England, April 2014 to March 2015. Health Protection Report. 2015. Available at . (Accessed Dec 21, 2017).
    1. National Center for Health Statistics 2016. Early release of selected estimates based on data From the January–June 2016 National Health Interview Survey (accessed Dec 21, 2017).
    1. Poethko-Muller C, Schmitz R. Vaccination coverage in German adults: results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56:845–57. PMID:23703506
    1. Organisation for Economic Co-operation and Development 2017. Influenza vaccination rates (indicator) . (accessed Dec 21, 2017).
    1. National Center for Immunization and Respiratory Diseases General recommendations on immunization — recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60:1–64.
    1. Christenson B, Hedlund J, Lundbergh P, Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J. 2004;23:363–8. doi:10.1183/09031936.04.00063504. PMID:15065822
    1. Kawakami K, Ohkusa Y, Kuroki R, Tanaka T, Koyama K, Harada Y, Iwanaga K, Yamaryo T, Oishi K. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine. 2010;28:7063–9. doi:10.1016/j.vaccine.2010.08.010. PMID:20723631
    1. Grilli G, Fuiano L, Biasio LR, Pregliasco F, Plebani A, Leibovitz M, Ugazio AG, Vacca F, Profeta ML. Simultaneous influenza and pneumococcal vaccination in elderly individuals. Eur J Epidemiol. 1997;13:287–91. doi:10.1023/A:1007398606807. PMID:9258527
    1. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012;8:81–88. doi:10.4161/hv.8.1.17623. PMID:22252006
    1. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11:760–8. doi:10.1016/S1473-3099(11)70090-1. PMID:21621466
    1. Musher DM, Manof SB, Liss C, McFetridge RD, Marchese RD, Bushnell B, Alvarez F, Painter C, Blum MD, Silber JL. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis. 2010;201:516–24. doi:10.1086/649839. PMID:20092407
    1. Chiba N, Morozumi M, Sunaoshi K, Takahashi S, Takano M, Komori T, Sunakawa K, Ubukata K, IPD Surveillance Study Group . Serotype and antibiotic resistance of isolates from patients with invasive pneumococcal disease in Japan. Epidemiol Infect. 2010;138:61–68. doi:10.1017/S0950268809990239. PMID:19538821
    1. Gilchrist SA, Nanni A, Levine O. Benefits and effectiveness of administering pneumococcal polysaccharide vaccine with seasonal influenza vaccine: an approach for policymakers. Am J Public Health. 2012;102:596–605. doi:10.2105/AJPH.2011.300512. PMID:22397339
    1. Hung IF, Leung AY, Chu DW, Leung D, Cheung T, Chan CK, Lam CL, Liu SH, Chu CM, Ho PL, et al.. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin Infect Dis. 2010;51:1007–16. doi:10.1086/656587. PMID:20887208
    1. Fletcher TJ, Tunnicliffe WS, Hammond K, Roberts K, Ayres JG. Simultaneous immunisation with influenza vaccine and pneumococcal polysaccharide vaccine in patients with chronic respiratory disease. BMJ. 1997;314:1663–5. doi:10.1136/bmj.314.7095.1663. PMID:9193290
    1. DeStefano F, Goodman RA, Noble GR, McClary GD, Smith SJ, Broome CV. Simultaneous administration of influenza and pneumococcal vaccines. JAMA. 1982;247:2551–4. doi:10.1001/jama.1982.03320430055032.
    1. Carlson AJ, Davidson WL, McLean AA, Vella PP, Weibel RE, Woodhour AF, Hilleman MR. Pneumococcal vaccine: dose, revaccination, and coadministration with influenza vaccine. Proc Soc Exp Biol Med. 1979;161:558–63. doi:10.3181/00379727-161-40596. PMID:39297
    1. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999–2011(1.). Emerg Infect Dis. 2013;19:1074–83. doi:10.3201/eid1907.121830. PMID:23763847
    1. Socan M, Frelih T, Janet E, Petras T, Peternelj B. Reactions after pneumococcal vaccine alone or in combination with influenza vaccine. Vaccine. 2004;22:3087–91. doi:10.1016/j.vaccine.2004.02.003. PMID:15297059
    1. Dransfield MT, Nahm MH, Han MK, Harnden S, Criner GJ, Martinez FJ, Scanlon PD, Woodruff PG, Washko GR, Connett JE, et al.. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180:499–505. doi:10.1164/rccm.200903-0488OC. PMID:19556517
    1. Mori S, Ueki Y, Akeda Y, Hirakata N, Oribe M, Shiohira Y, Hidaka T, Oishi K. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis. 2013;72:1362–6. doi:10.1136/annrheumdis-2012-202658. PMID:23345600
    1. Oishi K, Yoshimine H, Watanabe H, Watanabe K, Tanimura S, Kawakami K, Iwagaki A, Nagai H, Goto H, Kudoh S, et al.. Drug-resistant genes and serotypes of pneumococcal strains of community-acquired pneumonia among adults in Japan. Respirology. 2006;11:429–36. doi:10.1111/j.1440-1843.2006.00867.x. PMID:16771912
    1. Marchese RD, Puchalski D, Miller P, Antonello J, Hammond O, Green T, Rubinstein LJ, Caulfield MJ, Sikkema D. Optimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulin G serotype-specific antipneumococcal antibodies in human serum. Clin Vaccine Immunol. 2009;16:387–96. doi:10.1128/CVI.00415-08. PMID:19158284
    1. Hirst GK. The quantitative determination of influenza virus and antibodies by means of red cell agglutination. J Exp Med. 1942;75:49–64. doi:10.1084/jem.75.1.49. PMID:19871167
    1. Cordonnier C, Labopin M, Chesnel V, Ribaud P, De La Camara R Martino R, Ullmann AJ, Parkkali T, Locasciulli A, Yakouben K. et al.. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis. 2009;48:1392–401. doi:10.1086/598324. PMID:19368505

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever